Sunovion Pharmaceuticals Inc. Announces Health Outcomes Data That Support The Consideration Of Brovana (Arformoterol Tartrate) Inhalation Solution For The Maintenance Treatment Of COPD At The American Thoracic Society (ATS) 2015 Annual Meeting

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced the results of two health outcomes studies and a placebo controlled randomized trial presented at the American Thoracic Society (ATS) 2015 Annual Meeting in Denver. Results from these studies demonstrated that a substantial proportion of hospitalized chronic obstructive pulmonary disease (COPD) patients are not provided maintenance treatments; one in three patients report low confidence in using COPD devices and a majority of these patients have low treatment adherence; and more patients on Brovana® (arformoterol tartrate) Inhalation Solution reported clinically significant improvements in health-status compared with placebo.

Help employers find you! Check out all the jobs and post your resume.